Similar articles for PMID: 17090794

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
1998	1
2002	2
2003	3
2004	2
2005	4
2006	14
2007	18
2008	10
2009	10
2010	6
2011	9
2012	12
2013	3
2014	4
2015	1
2016	4
2017	3
2019	1
2020	2
2021	0

104 results

Results by year

Page 1

Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes.

Hinnen D, Nielsen LL, Waninger A, Kushner P. Hinnen D, et al. J Am Board Fam Med. 2006 Nov-Dec;19(6):612-20. doi: 10.3122/jabfm.19.6.612. J Am Board Fam Med. 2006. PMID: 17090794 Free article.

Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.

Nielsen LL. Nielsen LL. Drug Discov Today. 2005 May 15;10(10):703-10. doi: 10.1016/S1359-6446(05)03460-4. Drug Discov Today. 2005. PMID: 15896683 Review.

Incretin-based therapies in type 2 diabetes mellitus.

Chia CW, Egan JM. Chia CW, et al. J Clin Endocrinol Metab. 2008 Oct;93(10):3703-16. doi: 10.1210/jc.2007-2109. Epub 2008 Jul 15. J Clin Endocrinol Metab. 2008. PMID: 18628530 Free PMC article. Review.

Incretins: their physiology and application in the treatment of diabetes mellitus.

Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S. Tasyurek HM, et al. Diabetes Metab Res Rev. 2014 Jul;30(5):354-71. doi: 10.1002/dmrr.2501. Diabetes Metab Res Rev. 2014. PMID: 24989141 Review.

Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.

Triplitt C, Wright A, Chiquette E. Triplitt C, et al. Pharmacotherapy. 2006 Mar;26(3):360-74. doi: 10.1592/phco.26.3.360. Pharmacotherapy. 2006. PMID: 16503716 Review.

[The incretin effect: a new therapeutic target in type 2 diabetes].

Féry F. Féry F. Rev Med Brux. 2007 Sep;28(4):329-35. Rev Med Brux. 2007. PMID: 17958029 French.

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

Iltz JL, Baker DE, Setter SM, Keith Campbell R. Iltz JL, et al. Clin Ther. 2006 May;28(5):652-65. doi: 10.1016/j.clinthera.2006.05.006. Clin Ther. 2006. PMID: 16861088 Review.

Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

Verspohl EJ. Verspohl EJ. Pharmacol Ther. 2009 Oct;124(1):113-38. doi: 10.1016/j.pharmthera.2009.06.002. Epub 2009 Jun 21. Pharmacol Ther. 2009. PMID: 19545590 Review.

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

Drucker DJ, Nauck MA. Drucker DJ, et al. Lancet. 2006 Nov 11;368(9548):1696-705. doi: 10.1016/S0140-6736(06)69705-5. Lancet. 2006. PMID: 17098089 Review.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ. Neumiller JJ. J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. J Am Pharm Assoc (2003). 2009. PMID: 19801361 Review.

104 results

Jump to page

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed